本帖最后由 老马 于 2012-1-13 21:20 编辑
9 b1 j6 l' `' F5 D
0 u( I. g9 W& ~. f爱必妥和阿瓦斯丁的比较
1 I% _6 w1 e3 ?) a5 T I
: M K1 _7 ?+ r1 x9 @& o- |8 bhttp://cancergrace.org/lung/2008/08/30/bms099-os-neg/0 o( b8 i: r0 i0 w. k
3 Z9 A( j5 r: l3 ]/ l8 }
) A k P' [- T3 ?. |& xhttp://cancergrace.org/lung/2007/12/27/platgem-erbitux-trial/+ a+ k; J4 x+ c" A, P
==================================================
9 R. w$ d$ g7 K7 ~- q8 `, p" sOverall survival with cisplatin–gemcitabine and bevacizumab or placebo as first-line therapy for nonsquamous non-small-cell lung cancer: results from a randomised phase III trial (AVAiL)
* J$ f5 S$ D# n/ N X* DPatients and methods: Patients (n = 1043) received cisplatin 80 mg/m2 and gemcitabine 1250 mg/m2 for up to six cycles plus bevacizumab 7.5 mg/kg (n = 345), bevacizumab 15 mg/kg (n = 351) or placebo (n = 347) every 3 weeks until progression. Primary end point was progression-free survival (PFS); OS was a secondary end point.9 c) \8 \" Y6 |3 D
Results: Significant PFS prolongation with bevacizumab compared with placebo was maintained with longer follow-up {hazard ratio (HR) [95% confidence interval (CI)] 0.75 (0.64–0.87), P = 0.0003 and 0.85 (0.73–1.00), P = 0.0456} for the 7.5 and 15 mg/kg groups, respectively. Median OS was >13 months in all treatment groups; nevertheless, OS was not significantly increased with bevacizumab [HR (95% CI) 0.93 (0.78–1.11), P = 0.420 and 1.03 (0.86–1.23), P = 0.761] for the 7.5 and 15 mg/kg groups, respectively, versus placebo. Most patients (～62%) received multiple lines of poststudy treatment. Updated safety results are consistent with those previously reported.
% p' G; h$ j$ ~. j* _
|
显身卡
